Any current/future new fundraising through debt or equity?

Rubicon Research Limited raised around INR 161 crores through IPO, with approximately INR 100 crores still unutilized as of May 2026. The unutilized IPO funds are partly planned for use in the Arena acquisition. Additionally, the Arena acquisition has been partly funded through debt of around INR 75 crores. The company is maintaining a "war chest" for any attractive inorganic acquisition opportunities as stated in their RHP strategy. No specific new acquisitions or fundraising plans (debt or equity) for FY 2027 have been disclosed; management will announce when there is certainty about any fut

Any current/future capex/capital investment/strategic investment?

Capex guidance for the next two years is projected to be close to INR 300 crores across various sites (Page 14). The Pithampur facility will be ramped up in the coming year to meet the strong demand (Page 14). Capex philosophy: capex will lag sustained demand; capex incurred only after proven long-term demand to avoid overcapacity (Page 14). Recent capex includes acquisition of the Pithampur facility and additional investments (Page 4). Part of cash outflow in investing activities includes capex of INR 800 million along with acquisition and other inorganic outflows (Page 4). The company is kee

Future growth expectations in sales/revenue/volumes?

Strong growth trajectory continues with broad-based demand across the product portfolio. Revenue for Q4 FY26 showed a 44% year-on-year growth, with sequential growth of around 8%. The company expects sustained demand and increased outsourcing for at least the next couple of quarters. Upcoming 24 product filings under US FDA review indicate a robust pipeline, with launches expected over the next 12 to 18 months. Pithampur facility ramp-up anticipated within 12 to 18 months post FDA inspection, enhancing internal manufacturing capacity. Capex of around INR 300 crores planned over the next two ye

Future growth expectations in earnings/operating earnings/profits/EPS?

Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY. For FY26, revenue grew 37%, EBITDA 52%, and PAT 84%, indicating healthy profitability trends. Management expects sustained revenue growth ahead driven by broad-based demand and new product launches (24 products under US FDA review). EBITDA margin guidance is maintained at 22%-23%, considering ongoing expenses (ESOP, Arinna acquisition, Pithampur costs) and potential raw material/logistics cost volatility. R&D productivity stands at 5.9x with continued focus on speci

Current/ Expected Orderbook/ Pending Orders?

Rubicon Research has a strong revenue visibility with broad-based demand across its portfolio. There are 24 products currently under review with the US FDA, indicating a robust pending approval pipeline. These 24 products under FDA review are expected to launch over the next 12 to 18 months, contributing to growth. Inventory levels have increased as part of preparation for upcoming product launches. The company is ramping up capacity, especially at its Pithampur facility, expected to reach decent utilization within 12 to 18 months post-FDA inspection. Demand is expected to be sustained and gro

IN US

Sale is live|00:00:00left today

Rubicon Research LtdQ1 FY26Pharmaceuticals & Biotechnology

Rubicon Research Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,417P/E: 94.0Market Cap: ₹15.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Strong growth trajectory continues with broad-based demand across the product portfolio.
→Revenue for Q4 FY26 showed a 44% year-on-year growth, with sequential growth of around 8%.
→The company expects sustained demand and increased outsourcing for at least the next couple of quarters.
→Upcoming 24 product filings under US FDA review indicate a robust pipeline, with launches expected over the next 12 to 18 months.
→Pithampur facility ramp-up anticipated within 12 to 18 months post FDA inspection, enhancing internal manufacturing capacity.
→Capex of around INR 300 crores planned over the next two years to support growth and capacity expansion.
→The company aims to maintain EBITDA margins at 22-23% while expanding sales.
→Confident in beating overall industry growth (IPM growth) by fiscal 2028.

Margin guidance

Category 3

→Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY.
→For FY26, revenue grew 37%, EBITDA 52%, and PAT 84%, indicating healthy profitability trends.
→Management expects sustained revenue growth ahead driven by broad-based demand and new product launches (24 products under US FDA review).
→EBITDA margin guidance is maintained at 22%-23%, considering ongoing expenses (ESOP, Arinna acquisition, Pithampur costs) and potential raw material/logistics cost volatility.
→R&D productivity stands at 5.9x with continued focus on specialty and drug-device combination portfolio, underpinning quality growth.
→Capex of around INR 300 crores is planned over the next two years to support capacity expansion, especially the ramp-up of Pithampur site expected within 12-18 months.
→Despite recent increases, finance costs may not decrease soon due to partial debt funding of acquisitions.
→Overall, the company targets sustained profitable growth with stable margins and expanding pipeline.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Rubicon Research Limited raised around INR 161 crores through IPO, with approximately INR 100 crores still unutilized as of May 2026.
→The unutilized IPO funds are partly planned for use in the Arena acquisition.
→Additionally, the Arena acquisition has been partly funded through debt of around INR 75 crores.
→The company is maintaining a "war chest" for any attractive inorganic acquisition opportunities as stated in their RHP strategy.
→No specific new acquisitions or fundraising plans (debt or equity) for FY 2027 have been disclosed; management will announce when there is certainty about any future transactions.
→Finance costs are currently elevated due to remaining debt repayments and financing of factoring receivables, as well as debt used for recent acquisitions.
→Finance cost may not reduce immediately due to recent acquisition-related debt.

Order book

→Rubicon Research has a strong revenue visibility with broad-based demand across its portfolio.
→There are 24 products currently under review with the US FDA, indicating a robust pending approval pipeline.
→These 24 products under FDA review are expected to launch over the next 12 to 18 months, contributing to growth.
→Inventory levels have increased as part of preparation for upcoming product launches.
→The company is ramping up capacity, especially at its Pithampur facility, expected to reach decent utilization within 12 to 18 months post-FDA inspection.
→Demand is expected to be sustained and growing, necessitating outsourced manufacturing until internal capex expansions are fully operational.

Capex plans

Yes

→Capex guidance for the next two years is projected to be close to INR 300 crores across various sites (Page 14).
→The Pithampur facility will be ramped up in the coming year to meet the strong demand (Page 14).
→Capex philosophy: capex will lag sustained demand; capex incurred only after proven long-term demand to avoid overcapacity (Page 14).
→Recent capex includes acquisition of the Pithampur facility and additional investments (Page 4).
→Part of cash outflow in investing activities includes capex of INR 800 million along with acquisition and other inorganic outflows (Page 4).
→The company is keeping a "war chest" for any interesting inorganic acquisition opportunities, aligned with their RHP strategy, indicating potential future strategic investments (Page 17).

How does Rubicon Research Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Rubicon Research Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Rubicon Research Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio